Shares of Renalytix Plc (NASDAQ:RNLX – Get Free Report) rose 5.7% during trading on Wednesday . The company traded as high as $0.23 and last traded at $0.21. Approximately 934,400 shares traded hands during trading, a decline of 36% from the average daily volume of 1,451,440 shares. The stock had previously closed at $0.20.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Renalytix in a report on Friday, July 12th.
Read Our Latest Report on RNLX
Renalytix Stock Performance
Institutional Trading of Renalytix
A hedge fund recently bought a new stake in Renalytix stock. Levin Capital Strategies L.P. purchased a new position in shares of Renalytix Plc (NASDAQ:RNLX – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 555,000 shares of the company’s stock, valued at approximately $128,000. Levin Capital Strategies L.P. owned 0.72% of Renalytix at the end of the most recent quarter. 9.92% of the stock is owned by hedge funds and other institutional investors.
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
See Also
- Five stocks we like better than Renalytix
- How to Evaluate a Stock Before Buying
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is the Nikkei 225 index?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- 3 Fintech Stocks With Good 2021 Prospects
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.